---
title: "International Assets Investment Management LLC Buys Shares of 12,191 Bio-Techne Co. (NASDAQ:TECH)"
description: "International Assets Investment Management LLC purchased a new stake in Bio-Techne Co. (NASDAQ: TECH) during the 4th quarter, according to the company's recent 13F filing with the Securities & Exchang"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/202576251.md"
published_at: "2024-04-23T08:17:28.000Z"
---

# International Assets Investment Management LLC Buys Shares of 12,191 Bio-Techne Co. (NASDAQ:TECH)

> International Assets Investment Management LLC purchased a new stake in Bio-Techne Co. (NASDAQ: TECH) during the 4th quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. The firm bought 12,191 shares valued at approximately $941,000. Other hedge funds also made changes to their positions in the company. Director Roeland Nusse sold 10,400 shares for a total value of $800,592.00. Bio-Techne Co. has a market cap of $9.87 billion and a price-to-earnings ratio of 45.51. The company recently paid a quarterly dividend.

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)International Assets Investment Management LLC purchased a new stake in Bio-Techne Co. (NASDAQ:TECH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,191 shares of the biotechnology company's stock, valued at approximately $941,000.

-   Bio-Techne, J2 Global And InMode Break Out Of Bases, Near Buy Points

A number of other hedge funds also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bio-Techne in the 3rd quarter valued at approximately $27,000. CVA Family Office LLC bought a new stake in shares of Bio-Techne during the fourth quarter valued at about $31,000. Federated Hermes Inc. acquired a new stake in Bio-Techne in the third quarter worth about $47,000. Clear Street Markets LLC grew its position in Bio-Techne by 255.8% in the 3rd quarter. Clear Street Markets LLC now owns 733 shares of the biotechnology company's stock valued at $50,000 after buying an additional 527 shares in the last quarter. Finally, Global Retirement Partners LLC increased its stake in Bio-Techne by 17.3% during the 3rd quarter. Global Retirement Partners LLC now owns 1,514 shares of the biotechnology company's stock valued at $101,000 after buying an additional 223 shares during the period. Institutional investors own 98.95% of the company's stock.

## Insiders Place Their Bets

**Ad** Banyan Hill Publishing

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

In other news, Director Roeland Nusse sold 10,400 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $76.98, for a total value of $800,592.00. Following the completion of the sale, the director now directly owns 43,097 shares of the company's stock, valued at $3,317,607.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.10% of the company's stock.

## Bio-Techne Stock Performance

Shares of TECH opened at $62.80 on Tuesday. The company has a 50-day moving average of $70.35 and a two-hundred day moving average of $68.61. The stock has a market cap of $9.87 billion, a price-to-earnings ratio of 45.51, a PEG ratio of 7.73 and a beta of 1.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.37 and a quick ratio of 3.03. Bio-Techne Co. has a one year low of $51.79 and a one year high of $89.91.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings data on Thursday, February 1st. The biotechnology company reported $0.33 EPS for the quarter, missing analysts' consensus estimates of $0.36 by ($0.03). Bio-Techne had a return on equity of 14.21% and a net margin of 19.58%. The firm had revenue of $272.60 million during the quarter, compared to analyst estimates of $277.48 million. On average, equities research analysts expect that Bio-Techne Co. will post 1.52 earnings per share for the current year.

## Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Investors of record on Monday, February 12th were paid a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend was Friday, February 9th. Bio-Techne's dividend payout ratio is currently 23.19%.

## Analysts Set New Price Targets

Several research firms have recently issued reports on TECH. Stephens decreased their price objective on shares of Bio-Techne from $92.00 to $87.00 and set an "overweight" rating for the company in a report on Friday, February 2nd. Royal Bank of Canada lowered their price target on Bio-Techne from $85.00 to $75.00 and set a "sector perform" rating on the stock in a research report on Friday, February 2nd. Scotiabank began coverage on Bio-Techne in a report on Thursday, February 8th. They issued a "sector outperform" rating and a $80.00 price objective for the company. Deutsche Bank Aktiengesellschaft lowered their target price on Bio-Techne from $85.00 to $82.00 and set a "buy" rating on the stock in a report on Thursday, April 18th. Finally, Stifel Nicolaus downgraded shares of Bio-Techne from a "buy" rating to a "hold" rating and set a $65.00 price target for the company. in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $83.90.

**Read Our Latest Stock Analysis on Bio-Techne**

## Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

## Read More

-   Five stocks we like better than Bio-Techne
-   Using the MarketBeat Stock Split Calculator
-   It’s Time to Buy Into the Super Micro Computer Stock Implosion
-   How to Calculate Return on Investment (ROI)
-   Merger or Not, Albertson’s Companies is a Good Buy
-   How is Compound Interest Calculated?
-   3 Cheap Stocks That Shouldn’t Be So

**Want to see what other hedge funds are holding TECH?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. (NASDAQ:TECH - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad)## Should you invest $1,000 in Bio-Techne right now?

Before you consider Bio-Techne, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.

While Bio-Techne currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

### Related Stocks

- [TECH.US - Bio-Techne](https://longbridge.com/en/quote/TECH.US.md)
- [NDAQ.US - Nasdaq](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| “硬件防御” 对冲 AI 焦虑，苹果与纳指相关性创 20 年新低 | AI 浪潮下，苹果因未深度卷入军备竞赛，与纳指相关性创 20 年新低，成为科技股动荡中的 “避风港”。在 AI 投资回报存疑及软件业面临颠覆的焦虑中，苹果凭借不易受冲击的硬件生态逆势突围。尽管存在估值偏高及增长放缓压力，其独特的 “AI 中 | [Link](https://longbridge.com/en/news/276301841.md) |
| 香港税务学会建议调整基本及已婚人士免税额 | 香港税务学会建议调整基本及已婚人士免税额，基本免税额由 13.2 万港元上调至 14.5 万港元，已婚人士免税额由 26.4 万港元上调至 29 万港元，均上调约 10%。此外，建议豁免首次置业印花税，调整贷款利息及住宅租金扣税上限，优化医 | [Link](https://longbridge.com/en/news/276425063.md) |
| 一文读懂 2026 年至今的全球市场：什么在涨？美股为何不行？这种趋势会持续吗？ | 高盛报告揭示 2026 年市场新风向：周期性资产上涨仍有空间；但 AI 等热门主题估值过高，高波动或成为未来常态；美元将持续疲软；建议警惕高估值板块，分散股票持仓、保持健康的非美敞口（包括新兴市场），以及较长期限指数波动率的做多头寸。 | [Link](https://longbridge.com/en/news/276406606.md) |
| 多家银行向甲骨文断贷，巨头甲骨文这是怎么了？ | 多家银行停止向甲骨文提供贷款，因其人工智能数据中心扩张融资困难，面临资金困境。甲骨文计划裁员 2 万至 3 万人，预计释放 80 亿至 100 亿美元现金流，并考虑出售 283 亿美元收购的医疗软件部门 Cerner。美国银行对甲骨文的融资 | [Link](https://longbridge.com/en/news/276292972.md) |
| 彭博社：苹果走出独立行情，股价与纳斯达克相关性创 20 年新低 | 彭博社报道称，苹果公司股价近期与纳斯达克的相关性降至 20 年新低，40 天相关性从 0.92 降至 0.21。市场策略师 Art Hogan 指出，苹果与科技同行分道扬镳，成为投资者的替代性选项。苹果未参与 AI 资本支出竞赛，且核心业务 | [Link](https://longbridge.com/en/news/276311646.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
